NDAORALTABLET, ORALLY DISINTEGRATINGPriority Review
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
Priority Review
NURTEC ODT (rimegepant sulfate) by Pfizer is gene-related peptide receptor antagonist. First approved in 2020.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NURTEC ODT is an oral, orally-disintegrating tablet containing rimegepant sulfate, a small-molecule CGRP receptor antagonist approved by the FDA in February 2020. It is indicated for the acute treatment of migraine in adults. The drug works by blocking calcitonin gene-related peptide (CGRP) signaling, a key pathway implicated in migraine pathophysiology.
$0.478BPart D
Peak12.5 years to LOEProduct is at peak commercial performance with 329,578 Part D claims in 2023, indicating a substantial and established sales infrastructure supporting robust team hiring.
Mechanism of Action
gene-related peptide receptor antagonist.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
Started Oct 2026
3,000 enrolled
Migraine With or Without Aura
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
Started Jul 2026
60 enrolled
Acute Treatment of Migraine
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Started May 2026
400 enrolled
Acute Treatment of Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Started Nov 2025
250 enrolled
Migraine
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Started Sep 2025
60 enrolled
MigraineTrigger Induced Migraine
Worked on NURTEC ODT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.